Please login to the form below
NICE
This page shows the latest NICE news and features for those working in and with pharma, biotech and healthcare.
Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
The decision from NICE makes Yescarta the first chimeric antigen receptor (CAR) T-cell therapy to be recommended for routine use on the NHS. ... Helen Knight, director of medicines evaluation at NICE, said: “I am delighted that we have been able to
Latest news
-
Alnylam’s RNAi therapeutic recommended by NICE for hereditary form of amyloidosis
Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been recommended by the National Institute for Health and Care Excellence (NICE) as an option for treating a hereditary form of amyloidosis, the RNA interference (RNAi) ... The decision from NICE makes
-
Takeda’s all-oral multiple myeloma triplet therapy recommended by NICE
Ninlaro with lenalidomide and dexamethasone improved clinical outcomes. Takeda’s Ninlaro (ixazomib) with lenalidomide and dexamethasone has been recommended by the National Institute for Health and Care Excellence (NICE) to treat ... This latest
-
AstraZeneca/Daiichi Sankyo’s Enhertu recommended by NICE for advanced breast cancer
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of HER2-positive unresectable or metastatic breast ... NICE will then use this data
-
The role of medical communications in building credibility for healthtech
However, it was not until 2017 that the FDA approved the first DTx to treat disease and NICE only provided its first guidance for a prescription DTx in May 2022.
-
Boehringer Ingelheim’s idiopathic pulmonary fibrosis treatment recommended by NICE
Boehringer Ingelheim’s Ofev (nintedanib) has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of idiopathic pulmonary fibrosis (IPF) in adults with a forced ... NICE estimated that more than 5, 200
More from news
Approximately 439 fully matching, plus 853 partially matching documents found.
Latest Intelligence
-
Omnichannel communications in Medical Affairs: closing the gap between aspiration and reality
Pre-COVID-19, much of this was optional, a nice-to-have; now, it’s critical.
-
The Age of Diversity, Equality and Inclusion
Industry understands that it will not solve this by saying nice words because that doesn’t translate to anything,” she said.
-
Rare disease drug development – real-world evidence innovations with historical controls
Some formal health technology assessment (HTA) guidance on the use of external controls (ECs) and RWE is available from the UK’s National Institute for Health and Care Excellence (NICE).
-
Are smart deals a clever solution to UK market access?
rare mutations, under the condition of additional RWE collection for NICE reassessment. ... To support this further, NICE has recently published its Real-World Evidence Framework, a ‘living document’ to facilitate best practice for planning,
-
Who needs to be trusted anyway?
OK, this is a massive oversimplification, but you get the point: the public’s opinion of the product and the company really hasn’t been anything but a ‘nice-to-have’.
More from intelligence
Approximately 12 fully matching, plus 143 partially matching documents found.
Latest appointments
-
Hanover appoints Ian Dodge to its senior adviser panel
Care Excellence (NICE) highly specialised technology lead Josie Godfrey (pictured centre left).
-
NICE looks internally for new chief executive
He was appointed in April 1999 when NICE was first established under Tony Blair’s ‘New Labour’ government. ... I am delighted that Gill has been appointed as NICE’s next chief executive.
-
Professor Carole Longson moves from NICE to the ABPI
The Association of the British Pharmaceutical Industry (ABPI) has attracted Professor Carole Longson away from the National Institute for Health and Care Excellence (NICE) to be its new chief scientific officer, ... She most recently spent the 18 years
-
New health ministers and re-appointments after reshuffle
Freeman's role is also tied into the Department for Business, Innovation and Skills and includes expanded responsibility for the Cancer Drugs Fund, NICE and MHRA, research and development, issues around
-
Virgo Health Education appoints new senior team
She has over 15 years' experience working in medical education and is a member of the ISMPP Ethics Committee, the NICE Implementation External Reference Group and part of the Royal Berkshire
More from appointments
Approximately 4 fully matching, plus 11 partially matching documents found.
Latest from PMHub
-
Could femtech be the answer to the gender health gap?
37. While the app is approved for sale in the UK and can be advertised to the public, NICE still argues that there is not yet sufficient evidence for the app ... Published September 10, 2018. Accessed November 4, 2021. Wilkinson E. NICE: More evidence
-
Action on Anti-microbial resistance: Will the UK rise to the challenge
NHS England’s MedTech funding mandate only covers technologies deemed effective (based on NICE guidance), cost-saving within three years of implementation (based on NICE modelling) and affordable (not exceeding £20 ... The UK Government, NHS and NICE
-
Precision versus personalised medicine
References. NICE. BNF. Cytotoxic Drugs. Available at: . Accessed November 2022. Cancer.net. What is targeted therapy? Available at: . Accessed November 2022. UptoDate. Overview of therapeutic monoclonal antibodies. Available at: . Accessed November
-
MISSION CRITICAL: HOW PHARMA CAN HELP THE NHS IMPROVE CARE FOR OLDER PEOPLE
NICE guidelines are also essential reading. Third, it is important to work with ICSs and the wider clinical community to raise awareness of disease and facilitate best practice.
-
Practical advice for Early Scientific Advice (ESA) in HTA submissions
According to Ross Selby, Head of Global Patient Access at Takeda Oncology via NICE: “Uncertainty is the prime reason that medicines struggle with HTA.
More from PMHub
Approximately 2 fully matching, plus 61 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Europe’s cancer community publishes new report on transforming patient care
- Eli Lilly announces $450m investment in US manufacturing site
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- ASH 2022: bad blood but big advances
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- MIT researchers develop AI model to detect future lung cancer risk
- Live Webinar: Streamlining Healthcare Delivery Through Digital Care Journeys
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- Boehringer reports positive phase 2 data for spesolimab in generalised pustular psoriasis
- Microfoundations matter
- 5 ways we’re enhancing our services to support our clients in 2023
- Sanofi/Regeneron’s Dupixent recommended by CHMP for atopic dermatitis in children
- EU outlines measures to mitigate antibiotic shortage across Europe
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Europe’s cancer community publishes new report on transforming patient care
- Pistoia Alliance launches free guide on implementing FAIR principles in clinical data
- This month in 1917: A tale of two Mercks
PMHub
Empowering Strategic Performance Ltd
OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...
Latest intelligence
- 5 ways we’re enhancing our services to support our clients in 2023
- Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023....
- ASH 2022: bad blood but big advances
- Five trends from this year’s ASH conference – and why even pop icons can’t compete with the playlist of innovation shaping haematology...
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
